Skip to main navigation

Skip to content

Careers
Contact Us
中文

Home
About
Research & Development
- Pipeline
- Technology Platforms
Therapies
Newsroom
Investors

Careers
Contact Us
中文

Press Releases

Overview
Press Releases
Events and Presentations
- Annual General Meeting
Corporate Governance
Stock Information
Financials
- SEC Filings
- Earnings Releases
Resources
- Email Alerts
- Contact IR

Year

Jun 05, 2023

Ciltacabtagene Autoleucel (cilta-cel) Reduced Risk of Disease Progression or Death by 74% vs Standard Regimens for Adult Patients with Relapsed and Refractory Multiple Myeloma in CARTITUDE-4 Study

Jun 02, 2023

Legend Biotech Announces Participation in Upcoming Investor Conferences

May 25, 2023

Legend Biotech Announces Submission to the European Medicines Agency for Expanded Use of CARVYKTI® (ciltacabtagene autoleucel)

May 18, 2023

Legend Biotech Reports First Quarter 2023 Results and Recent Highlights

May 16, 2023

Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings

May 11, 2023

Legend Biotech Announces Participation in Upcoming Investor Conference

May 08, 2023

Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares

Apr 11, 2023

Legend Biotech Announces Appointment of Chief Medical Officer

Apr 03, 2023

Legend Biotech Establishes Strategic Advisory Board

Mar 30, 2023

Legend Biotech Reports Full-Year 2022 Results and Recent Highlights

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 16

GLOBAL HEADQUARTERS

2101 COTTONTAIL LANE

SOMERSET, NJ 08873, USA

+1-732-317-5050

Footer Links

ABOUT US
RESEARCH & DEVELOPMENT
THERAPIES
NEWSROOM
CAREERS
ETHICS & COMPLIANCE
COMPLIANCE HOTLINE
INVESTORS
COOKIE POLICY
PRIVACY POLICY
LEGAL NOTICE
CONTACT US
SITE MAP

© Legend Biotech 2023. All rights reserved. dedication

You are about to leave LegendBiotech.com